Reardon Andrew bought LGND
March 4, 2025 · Form 4 insider transaction
Reardon Andrew bought 28,043 shares of Ligand Pharmaceuticals Incorporated at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
28,043
Price
$0.00
Total value
N/A
InsiderReardon Andrew
Role—
SecurityEmployee Stock Option (right to buy)
Transaction codeA: Grant or award
Transaction dateMarch 4, 2025
Filing dateMarch 6, 2025
Shares owned after28,043
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.